BloombergRemember that young CEO who caused massive outrage by raising the price of an AIDS and cancer treatment drug overnight by 5,000 per cent? Yeah, him. Well he has only gone and got his comeuppance.
Known for boasting his excessive wealth all over social media, Martin Shkreli – who owns Turing Pharmaceuticals – now faces vigorous competition after a rival competitor fiercely undercut the pill Shkreli is charging $750 for, at just $1.
@MartinShkreli/TwitterImprimis Pharmaceuticals – who have began selling their version of the drug for $99 for 100 pills – were only previously marketed by Turing Pharmaceuticals.
Shkreli received heavy criticism from all four corners of the globe after essentially pricing poorer people out of life, with both The Infectious Diseases Society of America (IDSA) and the HIV Medicine Association condemning his actions and saying the price increase was ‘unjustifiable’ – well, no shit.
Imprimis’ CEO, Mark Baum told the AP news agency:
We are looking at all of these cases where the sole-source generic companies are jacking the price way up. There’ll be many more of these.
Just when you think you couldn’t despise him any more US Uncut reportedly tried to reach Shkreli for comment and his only response was ‘lol’.
@MartinShkreli/TwitterThat just sums him up really…
